RNS Number : 5211K Renalytix AI PLC 05 January 2021 This announcement contains inside information Renalytix AI plc (" RenalytixAI " or the " Company ") Early Risk Identification at Core of Innovative Kidney Care Partnership Between RenalytixAI, DaVita First-of-its-kind program combines
NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announced the
RNS Number : 3438K Renalytix AI PLC 04 January 2021 Renalytix AI plc (" RenalytixAI " or the " Company ") RenalytixAI to Present at the 39 th Annual J.P. Morgan Healthcare Conference NEW YORK , 4 January 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial
RNS Number : 8167H Renalytix AI PLC 07 December 2020 Renalytix AI plc (" RenalytixAI " or the " Company ") Result of AGM Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney
RNS Number : 3041H Renalytix AI PLC 02 December 2020 Renalytix AI plc (" RenalytixAI " or the " Company ") Partnership with National Kidney Foundation to improve management of Early Stage Kidney Disease Program focused on improving disease management and outcomes beginning at the primary
RNS Number : 5461G Renalytix AI PLC 26 November 2020 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 5327G Renalytix AI PLC 25 November 2020 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension
RNS Number : 5304G Renalytix AI PLC 25 November 2020 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders
NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported
RNS Number : 3896G Renalytix AI PLC 25 November 2020 Renalytix AI plc ("RenalytixAI" or the "Company") RenalytixAI Reports Financial Results for First Quarter of Fiscal Year 2021 NEW YORK , November 25, 2020 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial
